Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Western Union Co (WU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Western Union Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Western Union Co trades at $7.73 (market cap $2.48B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and Western Union Co pays a 11.82% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WU | |
|---|---|---|
Market Cap | $4.49B | $2.48B |
Sector | Health | Technology |
52-Week High | $28.06 | $10.28 |
52-Week Low | $20.06 | $7.04 |
Enterprise Value | $3.69B | $2.18B |
Dividend Yield | — | 11.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Western Union (WU) trades at $7.95, down 0.75% on the day, with mixed technical signals but a bullish overall trend. The stock shows strong profitability with a 10.88% net margin and 47.66% ROE, and valuation metrics like a P/E of 5.87 and P/S of 0.63 appear attractive. Recent developments include a partnership with Total Wireless for fee-free money transfers and progress on the Intermex acquisition, signaling digital expansion. However, Q1 2026 earnings missed expectations, and the company faces a high debt load with a debt-to-asset ratio of 34.64% as of 2025.
The outlook for WU is cautiously optimistic, with potential upside from digital growth initiatives and a high dividend yield, but risks include competitive pressures, recent earnings volatility, and significant leverage. Analyst sentiment is mixed, with a majority Hold rating, reflecting balanced views on growth prospects versus financial constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
